These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 25020273)

  • 1. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R; Green M; Patel B; Wagg J
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J; Zhong N; Newlands A; Church A; Goh AH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
    Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
    Kelleher DL; Mehta RS; Jean-Francois BM; Preece AF; Blowers J; Crater GD; Thomas P
    PLoS One; 2012; 7(12):e50716. PubMed ID: 23284643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R; Hardes K; Kelleher D; Preece A; Tombs L; Brealey N
    Clin Ther; 2014 Jul; 36(7):1016-1027.e2. PubMed ID: 24947493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
    Kempsford R; Allen A; Kelly K; Saggu P; Crim C
    Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
    Riley JH; Tabberer M; Richard N; Donald A; Church A; Harris SS
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1873-80. PubMed ID: 27578968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF; Niewoehner D; Brooks J; O'Dell D; Church A
    Respir Res; 2014 Jul; 15(1):78. PubMed ID: 25015176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.